背景:慢性骶髂关节炎具有不同的病因和多种疗效的治疗方法。近年来,一种利用骨基质的新型后路已经开发出来,尽管迄今为止,关于这种方法的疗效和安全性的文献数据有限.与横向入路相比,所描述的益处包括减少的不良后果和更快的恢复。
目的:本研究集中于后路骶髂关节融合术和包括残疾在内的转归,疼痛,术后使用镇痛药。
方法:本回顾性研究,进行了单中心研究,评估了骶髂融合同种异体移植植入物(来自PainTEQ的LinQ植入系统;来自OmniaMedical的PsiF系统)的安全性和有效性.
方法:共72例后入路骶髂关节融合术。在2020年8月至2024年6月期间,有53人在LSUHealthShreveport注册并随访为唯一的研究地点。选定的参与者年龄在28至79岁之间,平均年龄53.4岁.LinQ植入系统是选择用于植入的主要手术硬件(83.0%),在其余情况下选择PsiF系统。
方法:VAS评分,残疾变化,不良结果,经后路骶髂关节融合术后,比较镇痛的使用情况。
结果:到指定终点时,SIJ疼痛强度的平均VAS评分从9.5cm的基线评分显着降低了3.6cm(6月1日,2024).在这方面,65.4%的患者经历了20%或更多的疼痛改善,38.5%的患者经历了50%或更多的疼痛改善,26.9%的患者疼痛改善了70%或更多.在整个研究期间,零(0)个与手术相关的不良事件,也没有发生术中或术后并发症。
结论:没有对照组的回顾性研究。54%(72个中的39个)完成了至少一年的随访。Further,退出率为26%。
结论:本研究的结果表明,在迄今为止涉及后入路骶髂关节融合术的最大单中心研究中,在三年期间内,有效的结果具有最小的不良反应和残疾改善。
BACKGROUND: Chronic
sacroiliitis has variable etiologies with numerous treatments of varying efficacy. In recent years, a novel posterior approach utilizing bone matrix has been developed although to date, there is limited data in the literature regarding efficacy and safety through this approach. Benefits described include reduced adverse outcomes and quicker recovery when compared to the lateral approach.
OBJECTIVE: The present investigation focused on sacroiliac joint fusion through the posterior approach and outcomes including disability, pain, and use of analgesics post-surgery.
METHODS: This retrospective, single-center
study was conducted evaluating safety and efficacy of sacroiliac fusion allograft implants (LinQ Implant System from PainTEQ; PsiF System from Omnia Medical).
METHODS: A total of 72 posterior approach sacroiliac joint fusions were performed. Fifty-three individuals were enrolled and followed at LSU Health Shreveport as the sole investigational site between August 2020 and June 2024. Selected participant age ranged between 28 and 79 years, with a mean age of 53.4 years. The LinQ Implant System was the primary surgical hardware selected for implantation (83.0%), with the PsiF System chosen in the remaining cases.
METHODS: VAS Scores, disability changes, adverse outcomes, and analgesic use were compared after sacroiliac joint fusion via the posterior approach.
RESULTS: Mean VAS Scores for SIJ Pain Intensity significantly decreased by 3.6 cm from a baseline score of 9.5 cm by the Specified End (June 1st, 2024). In this regard, 65.4% of patients experienced a 20% or greater improvement in pain, 38.5% of patients experienced a 50% or greater improvement in pain, and 26.9% of patients experienced a 70% or greater improvement in pain. Zero (0) procedure-related adverse events nor intra- or post-operative complications occurred throughout the duration of the investigation.
CONCLUSIONS: Retrospective nature of the
study without a control group. Fifty-four percent (39 of 72) completed minimum one year follow up. Further, the withdrawal rate was 26%.
CONCLUSIONS: The results of the present investigation demonstrated effective outcomes with minimal adverse effects and improvements in disability over a three-year period in the largest single center
study to date involving posterior approach sacroiliac joint fusion.